Aratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics. The company markets GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; ENTYCE for appetite stimulation in dogs; and NOCITA, a post-operative anesthetic for cranial cruciate ligament surgery in dogs. The company is also developing AT-002 for evaluating capromorelin for weight management in cats with chronic kidney disease; AT-003, a bupivacaine liposome injectable suspension for post-operative pain management in cats; AT-006, an anti-viral for the treatment of feline herpes virus-induced ophthalmic conditions for cats; AT-016, an adipose-derived allogeneic stem cell therapeutic candidate for the treatment of osteoarthritis pain in dogs; and AT-018, an oral CRTH2 antagonist for the potential treatment of atopic dermatitis in dogs. In addition, the companyÂ’s licensed products include BLONTRESS, a canonized monoclonal antibody for the treatment of B-cell lymphoma in dogs; and TACTRESS, a canonized monoclonal antibody for the treatment of T-cell lymphoma in dogs, as well as AT-014, a novel her2/neu-directed cancer immunotherapy for the treatment of canine osteosarcoma for dogs. It has collaboration agreement with Elanco Animal Health, Inc. to develop, manufacture, and commercialize GRAPIPRANT products. Aratana Therapeutics, Inc. was founded in 2010 and is headquartered in Leawood, Kansas.
